Trace.Space: Your Design Changed. What Did Your Tests Miss?

Overview: How Trace.Space’s AI-Driven Requirements, Risk & Design Traceability Platform Transforms MedTech Development

Trace.Space is an AI-assisted systems engineering platform that supports requirements, risk and design traceability by connecting requirements, design parameters, tests and product configurations in a shared data model. In medical-device development, this approach addresses a documentation bottleneck: changes recorded in separate files or systems can make it difficult to establish which specifications and verification activities need review. The platform makes dependencies visible across product versions and variants, helping maintain continuity between design decisions and test evidence.

Its technical foundation is a graph that represents engineering records and their relationships. AI assists with structuring requirements, suggesting trace links and identifying missing context, while deterministic rules check consistency, broken links, coverage gaps and parameter tolerances. Space Agent adds AI-assisted analysis within this connected model, including change-impact and coverage analysis. Engineers review, accept or override suggestions rather than delegating design decisions to the system.

By keeping test results and requirements connected, Trace.Space can reduce manual cross-checking and help focus reviews on records affected by a change. This may limit avoidable rework and make verification planning more informed, particularly where several configurations share components or requirements. These are workflow benefits rather than demonstrated clinical outcomes; the live site presents a cross-industry engineering platform and does not provide healthcare-specific outcome evidence.

Last checked on October 26, 2026: Trace.Space’s September 2026 Trinity launch expanded its requirements-management offering into connected testing, design parameters, product variants and AI-agent-assisted engineering.

What is Trace.Space?

Trace.Space is an AI-assisted systems engineering platform that connects requirements, risks, design parameters, tests and product configurations to support traceability, change-impact analysis and verification-coverage review. It is designed for engineering teams developing complex hardware and safety-critical products, with potential applications in MedTech development rather than clinical care. Its technical approach combines a shared engineering graph, deterministic consistency checks and engineer-reviewed AI suggestions; the vendor states that it holds ISO 27001 certification and SOC 2 Type 2 assurance, but the homepage does not provide healthcare-specific validation evidence.

Intended Use and Limitations

• Trace.Space reports SOC 2 Type II assurance; buyers should request the auditor’s report to confirm its scope, assessment period and exceptions.

• ISO 27001 status is described inconsistently as “certified” and “compliant” across vendor pages; a current certificate and scope are needed to establish certification.

• The vendor states GDPR and CCPA compliance, including data-subject rights and breach-notification procedures; these are vendor commitments rather than independent privacy certifications.

• Customer data is not used to train or improve AI models unless explicitly authorised through a written addendum; the vendor also states that inference is transient and organisation-specific embeddings remain isolated.

• On-premise and fully air-gapped deployments are offered, with local AI inference through Trace.Rack and no external network calls in the air-gapped configuration.

• Published security controls include AES-256 encryption at rest, TLS 1.2+ in transit, role-based permissions, single sign-on and exportable audit logs.

• The vendor states that AI recommendations pass through engineering review before implementation, retaining human oversight of changes to engineering records.

• Its medical-device offering explicitly links ISO 14971 risk analysis, risk controls and verification evidence; this workflow support does not establish FDA clearance or CE marking for Trace.Space.

• Trace.Space’s September 2026 Trinity announcement reports $6 million in cumulative funding, including investment from Cherry Ventures; this is a corporate funding disclosure, not evidence of healthcare validation.